当前位置: X-MOL 学术Bioorg. Med. Chem. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
Bioorganic & Medicinal Chemistry Letters ( IF 2.5 ) Pub Date : 2020-01-25 , DOI: 10.1016/j.bmcl.2020.126986
John T Randolph 1 , Tongmei Li 1 , A Chris Krueger 1 , Howard R Heyman 1 , Hui-Ju Chen 1 , Daniel A J Bow 1 , Cecilia Van Handel 1 , Vincent Peterkin 1 , Robert A Carr 1 , DeAnne Stolarik 1 , Tatyana Dekhtyar 1 , Michelle Irvin 1 , Preethi Krishnan 1 , Rolf Wagner 1 , David A DeGoey 1
Affiliation  

Our HCV research program investigated novel 2'-dihalogenated nucleoside HCV polymerase inhibitors and identified compound 1, a 5'-phosphoramidate prodrug of 2'-deoxy-2'-α-bromo-β-chloro uridine. Although 1 had a favorable in vitro activity profile in HCV replicons, oral dosing in dog resulted in low levels of the active 5'-triphosphate (TP) in liver. Metabolism studies using human hepatocytes provided a simple assay for screening alternative phosphoramidate prodrug analogs. Compounds that produced high TP concentrations in hepatocytes were tested in dog liver biopsy studies. This method identified 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrug 14, which provided 100-fold higher TP concentrations in dog liver in comparison to 1 (4 and 24 h after 5 mg/kg oral dose).

中文翻译:

发现用于递送核苷 HCV NS5B 聚合酶抑制剂的 2-氨基异丁酸乙酯 (AIBEE) 氨基磷酸酯前药。

我们的 HCV 研究计划研究了新型 2'-二卤化核苷 HCV 聚合酶抑制剂,并确定了化合物 1,即 2'-deoxy-2'-α-bromo-β-chloro 尿苷的 5'-phosphoramidate 前药。尽管 1 在 HCV 复制子中具有良好的体外活性特征,但在狗中口服给药导致肝脏中活性 5'-三磷酸 (TP) 水平低。使用人肝细胞的代谢研究提供了一种用于筛选替代性氨基磷酸酯前药类似物的简单测定。在狗肝活检研究中测试了在肝细胞中产生高 TP 浓度的化合物。该方法鉴定了 2-氨基异丁酸乙酯 (AIBEE) 氨基磷酸酯前药 14,与 1 相比(口服 5 mg/kg 后 4 和 24 小时),它在狗肝脏中的 TP 浓度高出 100 倍。
更新日期:2020-01-26
down
wechat
bug